Given our discovery of HSF1's novel role in epigenetic regulation, combining inhibitors targeting HSF1, MYCN, and HDACs may offer new avenues for exploring therapeutic potentials and clinical value in HCC treatment. This evidence concerns the gene HSF1 and hepatocellular carcinoma.